Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Differential inactivation of polymorphic variants of human O6-alkylguanine-DNA alkyltransferase.

Fang Q, Loktionova NA, Moschel RC, Javanmard S, Pauly GT, Pegg AE.

Biochem Pharmacol. 2008 Feb 1;75(3):618-26. Epub 2007 Oct 2.

2.

Differences in the rate of repair of O6-alkylguanines in different sequence contexts by O6-alkylguanine-DNA alkyltransferase.

Coulter R, Blandino M, Tomlinson JM, Pauly GT, Krajewska M, Moschel RC, Peterson LA, Pegg AE, Spratt TE.

Chem Res Toxicol. 2007 Dec;20(12):1966-71. Epub 2007 Nov 1.

PMID:
17975884
3.

Inactivation of O(6)-alkylguanine-DNA alkyltransferase by folate esters of O(6)-benzyl-2'-deoxyguanosine and of O(6)-[4-(hydroxymethyl)benzyl]guanine.

Javanmard S, Loktionova NA, Fang Q, Pauly GT, Pegg AE, Moschel RC.

J Med Chem. 2007 Oct 18;50(21):5193-201. Epub 2007 Sep 20.

4.

Role of GADD34 in modulation of cisplatin cytotoxicity.

Fishel ML, Rabik CA, Bleibel WK, Li X, Moschel RC, Dolan ME.

Biochem Pharmacol. 2006 Jan 12;71(3):239-47. Epub 2005 Dec 1.

PMID:
16325149
5.

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, Provenzale JM, Gururangan S, Dancey JE, Maxwell J, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS.

J Clin Oncol. 2005 Oct 1;23(28):7178-87.

PMID:
16192602
6.

A bifunctional DNA repair protein from Ferroplasma acidarmanus exhibits O6-alkylguanine-DNA alkyltransferase and endonuclease V activities.

Kanugula S, Pauly GT, Moschel RC, Pegg AE.

Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3617-22. Epub 2005 Feb 24.

7.

Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine.

Fishel ML, Gamcsik MP, Delaney SM, Zuhowski EG, Maher VM, Karrison T, Moschel RC, Egorin MJ, Dolan ME.

Cancer Chemother Pharmacol. 2005 Apr;55(4):333-342. doi: 10.1007/s00280-004-0901-3. Epub 2004 Oct 2.

PMID:
15723259
8.

Beta-glucuronidase-cleavable prodrugs of O6-benzylguanine and O6-benzyl-2'-deoxyguanosine.

Wei G, Loktionova NA, Pegg AE, Moschel RC.

J Med Chem. 2005 Jan 13;48(1):256-61.

PMID:
15634019
9.

Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations.

Bacolod MD, Johnson SP, Pegg AE, Dolan ME, Moschel RC, Bullock NS, Fang Q, Colvin OM, Modrich P, Bigner DD, Friedman HS.

Mol Cancer Ther. 2004 Sep;3(9):1127-35.

10.

Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity.

Fishel ML, Newell DR, Griffin RJ, Davison R, Wang LZ, Curtin NJ, Zuhowski EG, Kasza K, Egorin MJ, Moschel RC, Dolan ME.

J Pharmacol Exp Ther. 2005 Jan;312(1):206-13. Epub 2004 Aug 10.

PMID:
15304523
11.

2-amino-O4-benzylpteridine derivatives: potent inactivators of O6-alkylguanine-DNA alkyltransferase.

Nelson ME, Loktionova NA, Pegg AE, Moschel RC.

J Med Chem. 2004 Jul 15;47(15):3887-91.

PMID:
15239666
12.

The repair of the tobacco specific nitrosamine derived adduct O6-[4-Oxo-4-(3-pyridyl)butyl]guanine by O6-alkylguanine-DNA alkyltransferase variants.

Mijal RS, Thomson NM, Fleischer NL, Pauly GT, Moschel RC, Kanugula S, Fang Q, Pegg AE, Peterson LA.

Chem Res Toxicol. 2004 Mar;17(3):424-34.

PMID:
15025514
14.

Enhancement of platinum-induced cytotoxicity by O6-benzylguanine.

Fishel ML, Delaney SM, Friesen LD, Hansen RJ, Zuhowski EG, Moschel RC, Egorin MJ, Dolan ME.

Mol Cancer Ther. 2003 Jul;2(7):633-40.

15.

O6-benzylguanine-mediated enhancement of chemotherapy.

Friedman HS, Keir S, Pegg AE, Houghton PJ, Colvin OM, Moschel RC, Bigner DD, Dolan ME.

Mol Cancer Ther. 2002 Sep;1(11):943-8.

16.

Repair of oligodeoxyribonucleotides by O(6)-alkylguanine-DNA alkyltransferase.

Luu KX, Kanugula S, Pegg AE, Pauly GT, Moschel RC.

Biochemistry. 2002 Jul 9;41(27):8689-97.

PMID:
12093287
17.

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.

Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS.

J Clin Oncol. 2002 May 1;20(9):2277-83.

PMID:
11980998
18.

Mutagenesis by O(6)-[4-oxo-4-(3-pyridyl)butyl]guanine in Escherichia coli and human cells.

Pauly GT, Peterson LA, Moschel RC.

Chem Res Toxicol. 2002 Feb;15(2):165-9.

PMID:
11849042
20.

Debenzylation of O(6)-benzyl-8-oxoguanine in human liver: implications for O(6)-benzylguanine metabolism.

Long L, Moschel RC, Dolan ME.

Biochem Pharmacol. 2001 Mar 15;61(6):721-6.

PMID:
11266657
22.

Inactivation of O6-alkylguanine-DNA alkyltransferase by 8-substituted O6-benzylguanine analogs in mice.

Ewesuedo RB, Wilson LR, Friedman HS, Moschel RC, Dolan ME.

Cancer Chemother Pharmacol. 2001;47(1):63-9.

PMID:
11221964
23.

Inactivation of human O(6)-alkylguanine-DNA alkyltransferase by modified oligodeoxyribonucleotides containing O(6)-benzylguanine.

Pegg AE, Goodtzova K, Loktionova NA, Kanugula S, Pauly GT, Moschel RC.

J Pharmacol Exp Ther. 2001 Mar;296(3):958-65.

PMID:
11181929
24.

Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long L, Friedman AH, Cokgor I, Colvin OM, Haglund MM, Ashley DM, Rich JN, Sampson J, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Stewart ES, Tourt-Uhlig S, Garcia-Turner AM, Herndon JE 2nd, Bigner DD, Dolan ME.

J Clin Oncol. 2000 Oct 15;18(20):3522-8.

PMID:
11032594
25.

Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and analogues in nonhuman primates.

Long L, Berg SL, Roy SK, McCully CL, Song-Yoo HW, Moschel RC, Balis FM, Dolan ME.

Clin Cancer Res. 2000 Sep;6(9):3662-9.

26.

O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials.

Keir ST, Dolan ME, Pegg AE, Lawless A, Moschel RC, Bigner DD, Friedman HS.

Cancer Chemother Pharmacol. 2000;45(6):437-40.

PMID:
10854129
27.

Potentiation of BCNU antitumor efficacy by 9-substituted O6-benzylguanines. Effect of metabolism.

Kokkinakis DM, Moschel RC, Pegg AE, Schold SC.

Cancer Chemother Pharmacol. 2000;45(1):69-77.

PMID:
10647505
28.

Inhibition of O(6)-methylguanine-DNA methyltransferase increases azoxymethane-induced colonic tumors in rats.

Wali RK, Skarosi S, Hart J, Zhang Y, Dolan ME, Moschel RC, Nguyen L, Mustafi R, Brasitus TA, Bissonnette M.

Carcinogenesis. 1999 Dec;20(12):2355-60.

PMID:
10590233
29.
30.

Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase.

Friedman HS, Pegg AE, Johnson SP, Loktionova NA, Dolan ME, Modrich P, Moschel RC, Struck R, Brent TP, Ludeman S, Bullock N, Kilborn C, Keir S, Dong Q, Bigner DD, Colvin OM.

Cancer Chemother Pharmacol. 1999;43(1):80-5.

PMID:
9923545
31.

Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

Friedman HS, Kokkinakis DM, Pluda J, Friedman AH, Cokgor I, Haglund MM, Ashley DM, Rich J, Dolan ME, Pegg AE, Moschel RC, McLendon RE, Kerby T, Herndon JE, Bigner DD, Schold SC Jr.

J Clin Oncol. 1998 Nov;16(11):3570-5.

PMID:
9817277
32.

Effect of ionic state of 2'-deoxyguanosine and solvent on its aralkylation by benzyl bromide.

Moon KY, Moschel RC.

Chem Res Toxicol. 1998 Jun;11(6):696-702.

PMID:
9625738
33.

O6-alkylguanine-DNA alkyltransferase inactivation by ester prodrugs of O6-benzylguanine derivatives and their rate of hydrolysis by cellular esterases.

Dolan ME, Roy SK, Garbiras BJ, Helft P, Paras P, Chae MY, Moschel RC, Pegg AE.

Biochem Pharmacol. 1998 May 15;55(10):1701-9.

PMID:
9634007
34.

Reaction of O6-benzylguanine-resistant mutants of human O6-alkylguanine-DNA alkyltransferase with O6-benzylguanine in oligodeoxyribonucleotides.

Pegg AE, Kanugula S, Edara S, Pauly GT, Moschel RC, Goodtzova K.

J Biol Chem. 1998 May 1;273(18):10863-7.

35.
36.
37.

Repair of O6-benzylguanine by the Escherichia coli Ada and Ogt and the human O6-alkylguanine-DNA alkyltransferases.

Goodtzova K, Kanugula S, Edara S, Pauly GT, Moschel RC, Pegg AE.

J Biol Chem. 1997 Mar 28;272(13):8332-9.

38.

Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.

Kurpad SN, Dolan ME, McLendon RE, Archer GE, Moschel RC, Pegg AE, Bigner DD, Friedman HS.

Cancer Chemother Pharmacol. 1997;39(4):307-16.

PMID:
9025771
39.
40.

Mechanism of depletion of O6-methylguanine-DNA methyltransferase activity in rat tissues by O6-Benzyl-2'-deoxyguanosine. Role of metabolism.

Kokkinakis DM, Moschel RC, Vuong TH, Reddy MV, Schold SC, Pegg AE.

In Vivo. 1996 May-Jun;10(3):297-306.

PMID:
8797031
41.

Treatment of human brain tumor xenografts with O6-benzyl-2'-deoxyguanosine and BCNU.

Schold SC Jr, Kokkinakis DM, Rudy JL, Moschel RC, Pegg AE.

Cancer Res. 1996 May 1;56(9):2076-81.

43.

Human liver oxidative metabolism of O6-benzylguanine.

Roy SK, Korzekwa KR, Gonzalez FJ, Moschel RC, Dolan ME.

Biochem Pharmacol. 1995 Oct 26;50(9):1385-9.

PMID:
7503788
45.

Specific labeling of O6-alkylguanine-DNA alkyltransferase by reaction with O6-(p-hydroxy[3H]methylbenzyl)guanine.

Ciocco GM, Moschel RC, Chae MY, McLaughlin PJ, Zagon IS, Pegg AE.

Cancer Res. 1995 Sep 15;55(18):4085-91.

46.

Mutagenesis in Escherichia coli by three O6-substituted guanines in double-stranded or gapped plasmids.

Pauly GT, Hughes SH, Moschel RC.

Biochemistry. 1995 Jul 11;34(27):8924-30.

PMID:
7612634
47.
48.

Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase.

Pegg AE, Dolan ME, Moschel RC.

Prog Nucleic Acid Res Mol Biol. 1995;51:167-223. Review. No abstract available.

PMID:
7659775
49.

Metabolism and disposition of O6-benzyl-2'-deoxyguanosine in Sprague-Dawley rats.

Kokkinakis DM, Moschel RC, Pegg AE, Dolan ME, Schold SC Jr.

Chem Res Toxicol. 1994 Nov-Dec;7(6):762-9.

PMID:
7696530
50.

Metabolism of O6-benzylguanine, an inactivator of O6-alkylguanine-DNA alkyltransferase.

Dolan ME, Chae MY, Pegg AE, Mullen JH, Friedman HS, Moschel RC.

Cancer Res. 1994 Oct 1;54(19):5123-30.

Supplemental Content

Loading ...
Support Center